Bioconjugate Chemistry · 2015 · 19 citations · 32 references
Life SciencesMolecular BiologyPharmaceuticsDrug DeliveryMolecular VirologyVirologyGene Delivery VectorsViral EntryViral InfectionsViral StructureViral TropismVirus EntryCell Surface Marker LigandsCell-specific TargetingGene-targeted TherapyParvovirus VectorsViral Envelope ProteinsViral Vector DeliveryViral VectorsVirally Derived Delivery Vectors
Viruses are evolutionarily developed cell-entering nanomachines, which are frequently used as gene or drug delivery systems. Parvovirus B19 (B19V) shows a remarkably restricted tropism for erythropoietin-dependent erythroid differentiation stages, and thus this virus provides an opportunity to deliver cargo to these intermediate differentiated cells. Here we report the construction of a delivery system from B19V subunits that maintains the highly selective cell-entry of the native virus and offers versatile cargo transport. To obtain this specific carrier, we conjugated the cell-targeting VP1u region of B19V to NeutrAvidin as a loading platform for biotinylated cargos. The VP1u-NeutrAvidin conjugate delivered fluorophores, DNA, and toxic payloads specifically to erythroid cells around the proerythroblast differentiation stage, including erythroleukemic cells. The VP1u-NeutrAvidin represents a unique cell surface marker which exclusively detects intermediate erythroid differentiation stages. Furthermore, the cell-entering property of this viral-based targeting system offers opportunities for erythroid-specific drug delivery or gene therapy.
32
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Svetlana O. Doronina, Brian E. Toki, Michael Torgov et al. · Nature Biotechnology · 2003 · 1.2K citations
Erythrocyte P Antigen: Cellular Receptor for B19 Parvovirus
Kevin Brown, Stacie M. Anderson, Neal S. Young · Science · 1993 · 859 citations
Ke Chen, Jing Liu, Susanne Heck et al. · Proceedings of the National Academy of Sciences · 2009 · 524 citations · Full text